Loading...
XNYS
MDT
Market cap130bUSD
Dec 04, Last price  
101.99USD
1D
0.02%
1Q
9.78%
Jan 2017
43.18%
Name

Medtronic PLC

Chart & Performance

D1W1MN
XNYS:MDT chart
P/E
28.06
P/S
3.90
EPS
3.63
Div Yield, %
2.05%
Shrs. gr., 5y
-0.92%
Rev. gr., 5y
3.01%
Revenues
33.54b
+3.62%
11,292,000,00012,299,000,00013,515,000,00014,599,000,00015,817,000,00015,933,000,00016,184,000,00016,590,000,00017,005,000,00020,261,000,00028,833,000,00029,710,000,00029,953,000,00030,557,000,00028,913,000,00030,117,000,00031,686,000,00031,227,000,00032,364,000,00033,537,000,000
Net income
4.66b
+26.82%
2,546,700,0002,802,000,0002,231,000,0002,169,000,0003,099,000,0003,096,000,0003,617,000,0003,467,000,0003,065,000,0002,675,000,0003,538,000,0004,028,000,0003,104,000,0004,631,000,0004,789,000,0003,606,000,0005,039,000,0003,758,000,0003,676,000,0004,662,000,000
CFO
7.04b
+3.79%
2,207,400,0002,979,000,0003,489,000,0003,878,000,0004,131,000,0003,741,000,0004,381,000,0004,883,000,0004,959,000,0004,902,000,0005,218,000,0006,880,000,0004,684,000,0007,007,000,0007,234,000,0006,240,000,0007,346,000,0006,039,000,0006,787,000,0007,044,000,000
Dividend
Sep 27, 20240.7 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
IPO date
Nov 21, 1977
Employees
95,000
Domiciled in
IE
Incorporated in
IE

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑042024‑042023‑042022‑042021‑042020‑042019‑042018‑042017‑042016‑04
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT